Subcutaneous injection
BPC-157
A synthetic protein fragment studied for tissue repair.
BPC-157 is a synthetic fragment of a protein found in gastric juice, studied for its role in tissue repair pathways. It has not been through the clinical trials the FDA requires to approve a drug. rhome's BPC-157 is compounded by a licensed pharmacy from your clinician's prescription.
From $149 per month1not FDA approved
Compounded under a temporary federal policy (HHS, October 28, 2026) while the FDA decides whether to add it to its compounding list. That is not FDA approval, and the policy can change.
Your rhythm
On the schedule your clinician sets.
What to expect
Living with BPC-157.
- 01
Clinician-set dose and schedule
- 02
Compounded by licensed U.S. pharmacies
- 03
Prescribed in defined courses, reviewed before any renewal
- 04
Progress check-ins built into your plan
Questions
Straight answers.
No. On October 28, 2026, the U.S. Department of Health and Human Services issued an interim enforcement-discretion policy: it does not intend to act against licensed pharmacies that compound this substance from a patient-specific prescription, under set conditions, while the FDA finishes its rulemaking. That is not FDA approval. The substance has not been evaluated by the FDA for safety, effectiveness, or quality the way an approved drug is, and it has not been added to the FDA's 503A bulk drug list; an FDA advisory committee recommended adding it in July 2026 and the FDA has not decided. The policy is temporary and can change.
Your clinician sets the length of a course and reassesses before any renewal.
Then a box at the door.
Your first box, in your treatment’s colour, with a card on top with your name on it.